Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.

Hajime Isomoto1, Justin L Mott, Shogo Kobayashi

  • 1Miles & Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.

Gastroenterology
|January 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the Perihilar Cholangiocarcinoma Risk Estimation of Tumor Recurrence After Transplant (PRETREAT) Score.

Annals of surgery·2025
Same author

Differential MYC Phosphorylation Drives the Divergent Cholangiocyte Response to Stress.

Cellular and molecular gastroenterology and hepatology·2025
Same author

Deep learning-based uncertainty quantification for quality assurance in hepatobiliary imaging-based techniques.

Oncotarget·2025
Same author

Deep learning analysis of MRI accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis.

Hepatology (Baltimore, Md.)·2025
Same author

The dynamic landscape of cholestatic liver disease.

Hepatology (Baltimore, Md.)·2025
Same author

Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models.

Hepatology (Baltimore, Md.)·2025

Epigenetic silencing of Suppressor of Cytokine Signaling 3 (SOCS-3) promotes cholangiocarcinoma growth by sustaining Interleukin 6 (IL-6)/STAT-3 signaling. Restoring SOCS-3 sensitizes cancer cells to apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Interleukin 6 (IL-6) signaling via STAT-3 is crucial in cholangiocarcinoma, promoting Mcl-1 expression and apoptosis resistance.
  • Suppressor of Cytokine Signaling 3 (SOCS-3) normally inhibits IL-6/STAT-3 signaling through a feedback loop.

Purpose of the Study:

  • To investigate the regulation of SOCS-3 in human cholangiocarcinoma.
  • To understand the role of SOCS-3 in IL-6/STAT-3 pathway dysregulation in this cancer.

Main Methods:

  • Assessed SOCS-3 protein expression in cholangiocarcinoma tissues and cell lines.
  • Analyzed SOCS-3 promoter methylation in tumor and non-tumor samples.
  • Utilized a demethylating agent (DAC) and enforced SOCS-3 expression in cell lines.

Related Experiment Videos

Main Results:

  • Found an inverse correlation between phospho-STAT-3 and SOCS-3 expression.
  • Demonstrated SOCS-3 promoter hypermethylation in tumors and cell lines lacking SOCS-3.
  • DAC treatment or SOCS-3 re-expression reduced phospho-STAT-3 and Mcl-1 levels.
  • Both interventions sensitized cells to TRAIL-induced apoptosis.

Conclusions:

  • Epigenetic silencing of SOCS-3 is a key mechanism driving sustained IL-6/STAT-3 signaling in cholangiocarcinoma.
  • This silencing leads to increased Mcl-1 expression and chemoresistance.
  • Restoring SOCS-3 function offers a potential therapeutic strategy.